Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
AssigneeCureVac AG
InventorsFlorian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
Claims23
A method for stimulating an immune response to an ebola virus antigen in a subject comprising administering an effective amount of a pharmaceutical composition comprising a modified mRNA that encodes an ebola virus glycoprotein to the subject, wherein said mRNA lacks any promoter sequences, and wherein the mRNA comprises an increased G/C content of at least 7% percentage points relative to a wild-type mRNA encoding the ebola virus glycoprotein.
Dependencies are inferred from the claim text.